Provided by Tiger Trade Technology Pte. Ltd.

Evommune

10.84
-2.2400-17.13%
Pre-market: 11.070.2300+2.12%07:00 EDT
Volume:3.99M
Turnover:44.16M
Market Cap:393.41M
PE:-4.15
High:12.10
Open:11.90
Low:10.30
Close:13.08
52wk High:33.20
52wk Low:10.30
Shares:36.29M
Float Shares:19.98M
Volume Ratio:7.31
T/O Rate:19.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.6090
EPS(LYR):-11.2228
ROE:-52.11%
ROA:-31.99%
PB:1.42
PE(LYR):-0.97

Loading ...

U.S. Stocks on the MOVE-Apple, Omnicom, Jersey Mike's Subs

Reuters
·
18 hours ago

Evommune Price Target Cut to $22.00/Share from $28.00 by Leerink Partners

Dow Jones
·
20 hours ago

Sweden's Biovica Q1 Sales Rise on Pharma Services Growth

Reuters
·
Yesterday

Stifel Nicolaus Remains a Buy on Evommune, Inc. (EVMN)

TIPRANKS
·
Yesterday

Analysts Are Bullish on These NA Stocks: Douglas AG (DOUDF), Evommune, Inc. (EVMN)

TIPRANKS
·
Yesterday

U.S. Stocks on the MOVE-UGI, Chewy, Cognyte Software

Reuters
·
Yesterday

Sector Update: Healthcare Stocks Mixed Premarket Wednesday

MT Newswires Live
·
Yesterday

Evommune price target lowered to $21 from $29 at RBC Capital

TIPRANKS
·
Yesterday

Leerink Partners Sticks to Its Buy Rating for Evommune, Inc. (EVMN)

TIPRANKS
·
Yesterday

U.S. Stocks on the MOVE-Meta, Chime Financial, ServiceTitan

Reuters
·
Yesterday

Evommune, Inc. : Raymond James Cuts Target Price to $18 from $32

THOMSON REUTERS
·
Yesterday

RBC Cuts Price Target on Evommune to $21 From $29, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Yesterday

Analysts Conflicted on These NA Names: Evommune, Inc. (EVMN) and Chime Financial, Inc. Class A (CHYM)

TIPRANKS
·
Yesterday

Evommune Slides 18.1% Premarket After Co's Eczema Drug Misses Main Goal in Mid-Stage Trial

THOMSON REUTERS
·
Yesterday

U.S. Research Roundup-Argan, Mastec, Oracle

Reuters
·
Yesterday

Evommune Scraps Eczema Drug After Trial Miss, Shares Plunge

Reuters
·
Yesterday

Evommune Phase 2b EV0756 trial did not meet primary and secondary endpoints

TIPRANKS
·
Yesterday

Evommune down 31% at $9 after Phase 2b EVO-756 study results

TIPRANKS
·
Yesterday

Evommune Says Evo756 Misses Endpoints in Phase 2b Atopic Dermatitis Trial

Reuters
·
Yesterday

Evommune, - Has Balance Sheet Supporting Operations into 2029

THOMSON REUTERS
·
Yesterday